Oliver Zuehlke - Bayer AG Member of the Supervisory Board

BAYRY
 Stock
  

USD 14.54  0.06  0.41%   

  Executive
Mr. Oliver Zuehlke was Independent Vice Chairman of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since July 2015. He was Member of the Supervisory Board and Employee Representative at the Company from April 27, 2007. He is Member of the Presidial CommitteeMediation Committee, the Audit Committee and the Innovation Committee at the Company. He joined Bayer AG in Leverkusen, Germany, in 1985 and trained as a chemical production technician. During his training, in 1988, he became a member of the body representing young employees and apprentices. He chaired this body from 1990 to 1994. He was elected a fulltime member of the Works Council at the Leverkusen site in 1994 and was Deputy Chairman from 2002 to 2010. Since then, he has also been a member of the Economics Committee of Bayer AG. In 2009, he completed a distance learning course on human resources management. Between 2010 and 2015 he was Chairman of the Works Council at the Leverkusen site and also held various functions in the German Mining, Chemical and Power Workers Union . He was a member of the District Executive, the Regional Executive, the federal industrial group for the chemical industry, and the advisory board. From 2009 to 2015 Zuehlke was Chairman of the Bayer European Forum. In 2014 he became Member of the Supervisory Board of Bayer Pharma AG. Since 2015 he was Chairman of the Central Works Council of Bayer AG.
Age: 49  Executive Since 2015      
49 214 30 1  https://www.bayer.com
Zuehlke is Chairman of the Works Council of the Leverkusen site of Bayer AG and is Chairman of the Bayer European Forum. He is Member of the Supervisory Board at Bayer Pharma AG since May, 2014. He is Member of the Human Resources Committee at the Company.

Bayer AG Management Efficiency

Bayer AG PK has return on total asset (ROA) of 5.76 % which means that it generated profit of $5.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.0 %, meaning that it generated $13.0 on every $100 dollars invested by stockholders. Bayer AG management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 44.79 B in total debt with debt to equity ratio (D/E) of 1.08, which is about average as compared to similar companies. Bayer AG PK has a current ratio of 1.14, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Bayer AG until it has trouble settling it off, either with new capital or with free cash flow. So, Bayer AG's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bayer AG PK sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bayer to invest in growth at high rates of return. When we think about Bayer AG's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

EXECUTIVE Since

Ashna ZaheerCoca-Cola Co
2019
Tim LeveridgeCoca-Cola Co
2015
Edmund SteinikeCoca-Cola Co
2013
Jennifer ManningCoca-Cola Co
2016
Joseph RomanelliMerck Company
2015
Julie HamiltonCoca-Cola Co
2016
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Aktienges is traded on OTC Exchange in the United States. Bayer AG PK [BAYRY] is a Pink Sheet which is traded between brokers over the counter.

Bayer AG PK Leadership Team

Elected by the shareholders, the Bayer AG's board of directors comprises two types of representatives: Bayer AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer AG's management team and ensure that shareholders' interests are well served. Bayer AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Brendelto, Vice President - Communications of the Consumer Health Division
Heike Hausfeld, Member of the Supervisory Board
Peter Hausmann, Member of the Supervisory Board
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division
Thomas Fischer, Member of the Supervisory Board
Marijn Dekkers, Chairman of Management Board and CEO
Detlef Rennings, Member of the Supervisory Board
Helmut Panke, Member of the Supervisory Board
Werner Wenning, Chairman of the Supervisory Board
Reiner Hoffmann, Member of the Supervisory Board
Sue Rataj, Member of the Supervisory Board
Petra ReinboldKnape, Member of the Supervisory Board
Dieter Weinand, Member of the Management Board and Head of the Pharmaceuticals Division, North America Region
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board
Kemal Malik, Member of Management Board, Chief Medical Officer of Bayer Healthcare and Head of Global Devel. - Bayer Healthcare
Petra Kronen, Member of the Supervisory Board
Oliver Zuehlke, Member of the Supervisory Board
Thomas Elsner, Member of the Supervisory Board
Alexander Rosar, Head of Investor Relations
Simone BagelTrah, Member of the Supervisory Board
Michael SchmidtKiessling, Member of the Supervisory Board
ErnstLudwig Winnacker, Member of the Supervisory Board
Colleen Goggins, Member of the Supervisory Board
Heinz Webers, Member of the Supervisory Board
Wolfgang Nickl, CFO, Member of the Management Board
Johanna Faber, Member of the Supervisory Board
Paul Achleitner, Member of the Supervisory Board
Klaus Sturany, Independent Member of the Supervisory Board
Frank Loellgen, Member of the Supervisory Board
Andre Broich, Member of the Supervisory Board
Liam Condon, Member of Management Board and CEO of Bayer Cropscience
Patrick Thomas, CEO, Bayer MaterialScience
Yueksel Karaaslan, Member of the Supervisory Board
Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division
Thomas Ebeling, Member of the Supervisory Board
Erica Mann, Member of the Management Board, Head of the Consumer Health Division
Norbert Bischofberger, Member of the Supervisory Board
Johannes Dietsch, CFO and Member of Management Board
Hartmut Klusik, Member of the Management Board, Director of Human Resources, Technology & Sustainability
Michael Koenig, Member of the Management Board responsible for Human Resources
Norbert Winkeljohann, Independent Member of the Supervisory Board
Clemens Boersig, Member of the Supervisory Board
Juergen Beunink, Interim Head of Investor Relations
Thomas Win, Vice Chairman of the Supervisory Board
Otmar Wiestler, Member of the Supervisory Board
Sabine Schaab, Member of the Supervisory Board
Wolfgang Plischke, Member of the Supervisory Board

Bayer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc pink sheet is not an easy task. Is Bayer AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bayer AG in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bayer AG's short interest history, or implied volatility extrapolated from Bayer AG options trading.

Pair Trading with Bayer AG

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bayer AG position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bayer AG will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bayer AG

+0.78JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to Bayer AG could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bayer AG when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bayer AG - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bayer AG PK to buy it.
The correlation of Bayer AG is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bayer AG moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bayer AG PK moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bayer AG can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for analysis

When running Bayer AG PK price analysis, check to measure Bayer AG's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bayer AG is operating at the current time. Most of Bayer AG's value examination focuses on studying past and present price action to predict the probability of Bayer AG's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bayer AG's price. Additionally, you may evaluate how the addition of Bayer AG to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Please note, there is a significant difference between Bayer AG's value and its price as these two are different measures arrived at by different means. Investors typically determine Bayer AG value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bayer AG's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.